Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Citius Oncology, Inc.NASDAQ: CTOR

EBITDA · Q2 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$26.81M, compared with -$7.47M a year earlier. Trailing-twelve-month EBITDA was -$41.08M.

Context

  • EBITDA increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Sep 2026, a step up from the -14.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.81M-476.4% QoQ
Last fiscal yearSep 2025
-$23.49M-14.2% YoY
LTMMar 2026
-$41.08M-63.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-258.8%+100.0%+358.8 pp
1 year-14.2%+100.0%+114.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(23.49M) USD
Year-over-year change
-14.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's LTM Mar 2026 EBITDA of -$41.08M is the 5th highest of the 10 companies compared; the peer median is -$41.87M.
  • Its year-over-year change of -63.2% is the 7th highest of 10, against a peer median of +23.4%.
  • EBITDA amounts to 732.1% of revenue for CTOR, versus a peer median of 582.2%.
CTOR Competitors Peer median
EBITDA for CTOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$449.13M +489.9%——
LNSRLENSAR, Inc.LTM Mar 2026$33.96M +165.0%—58.8%
SPROSpero Therapeutics, Inc.LTM Mar 2026$14.89M +121.1%—27.2%
ACTUActuate Therapeutics IncLTM Mar 2026-$21.52M +14.5%——
CTORCitius Oncology, Inc.LTM Mar 2026-$41.08M -63.2%—732.1%
MCRBSeres Therapeutics, Inc.LTM Mar 2026-$41.87M +24.2%—3650.0%
OWLTOwlet, Inc.LTM Mar 2026-$43.26M -365.8%—40.4%
FBRXForte Biosciences, Inc.LTM Mar 2026-$74.38M -70.3%——
FATEFate Therapeutics, Inc.LTM Mar 2026-$117.42M +23.4%—1859.1%
SCLXScilex Holding CompanyLTM Mar 2026-$374.35M -462.2%—1105.5%
Peer median (excluding CTOR) -$41.87M+23.4%—582.2%

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development6.86M4.24M4.93M6.42M
Selling, General & Admin2.86M7.88M15.65M17.1M
Operating Expenses9.71M12.12M20.57M23.52M
Depreciation & Amortization9.71M000
EBITDA0(12.12M)(20.57M)(23.49M)
EBITDA Margin————
Operating Income(9.71M)(12.12M)(20.57M)(23.52M)
Operating Margin————
Interest Income00036.37K
Interest Expense000218.03K
Other Income / Expenses000(181.66K)
Income Before Tax(9.71M)(12.12M)(20.57M)(23.7M)
Pre-Tax Margin————
Income Tax Expense1.15M576K576K1.06M
Net Income(10.87M)(12.7M)(21.15M)(24.76M)
Net Margin————
EPS (Basic)(0.08)(0.19)(0.30)(0.34)
EPS (Diluted)(0.08)(0.19)(0.30)(0.34)
Weighted Avg Shares90.16M89.48M71.55M73.27M
Weighted Avg Shares (Diluted)90.16M89.48M71.55M73.27M

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.